Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab

Documenti analoghi

• Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
  di: Braun, Jürgen, et al.
  Pubblicazione: (2011)
• Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
  di: Deodhar, Atul, et al.
  Pubblicazione: (2015)
• The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
  di: Braun, Jürgen, et al.
  Pubblicazione: (2014)
• Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
  di: Braun, Jürgen, et al.
  Pubblicazione: (2011)
• Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study
  di: Inman, Robert D., et al.
  Pubblicazione: (2016)